Izutsu, Koji http://orcid.org/0000-0002-9941-2448
Minami, Yosuke
Fukuhara, Noriko
Terui, Yasuhito
Jo, Tatsuro
Yamamoto, Go
Ishikawa, Takayuki
Kobayashi, Tsutomu
Kiguchi, Toru
Nagai, Hirokazu
Ohtsu, Tomoko
Kalambakas, Stacey
Fustier, Pierre
Midorikawa, Shuichi
Tobinai, Kensei
Funding for this research was provided by:
Celgene (N/A)
Article History
Received: 9 September 2019
Revised: 6 December 2019
Accepted: 10 December 2019
First Online: 19 December 2019
Compliance with ethical standards
:
: KI reports grants from Celgene during the conduct of the study; grants and personal fees from Celgene, Eisai, MSD, Takeda, Janssen, Mundipharma, Chugai, Astra Zeneca, Abbvie, Bayer, and Zenyaku outside the submitted work; personal fees from Bristol Myers Squib, Dainihon Sumitomo, Nihon Mediphysics, and Kyowa Hakko Kirin outside the submitted work; and grants from Ono, Gilead, Solasia, Symbio, Astellas Amgen, and Daiichi Sankyo outside the submitted work. YM reports research funding from Ono Pharmaceutical and lecture fees from BMS, Novartis, and Pfizer outside the submitted work. NF reports grants from Celgene K.K. during the conduct of the study; grants and personal fees from Eisai and Takeda outside the submitted work; grants from Abbvie, Bayer, Gilead and Solasia Pharma outside the submitted work; and personal fees from Celgene, Chugai, Janssen, Kyowa Hakko Kirin, Mochida, Mundi, Nippon Shinyaku, Ono and Zenyaku outside the submitted work. GY reports personal fees from Celgene, Kyowa Hakko Kirin, Takeda, Bristol-Myers Squibb, Mundipharma, and Janssen outside the submitted work; and grants and personal fees from Chugai Pharma and Eisai outside the submitted work. HN reports grants from Celgene Corporation during the conduct of the study; grants and personal fees from Janssen Pharmaceutical K. K, Celgene Corporation, Mundipharma K.K., Bayer Yakuhin, Takeda Pharmaceutical, Kyowa Hakko Kirin, Esai, Bristol-Myers Squibb, Ono Pharmaceutical, Gilead Sciences, Zenyaku Kogyo, AstraZeneca, SymBio Pharmaceuticals, Otsuka Pharmaceutical, and Roche; grants from Abbvie G.K., Solasia Pharma K.K., HUYA Bioscience International, IQVIA Japan K.K.; and personal fees from Sanofi K.K. outside the submitted work. TO reports employment and stockholder with Celgene K.K. during the conduct of the study. SK reports employment and stockholder with Celgene during the conduct of the study. PF reports employment, stockholder, and received personal fees from Celgene during the conduct of the study. SM reports employment with Celgene K.K. and stockholder of Celgene. KT reports grants and personal fees from Celgene during the conduct of the study; personal fees from Zenyaku, HUYA Bioscience International, Yakult, Daiichi Sanky, Bristol-Myers Squibb, Meiji Seika Kaisha, Solasia Pharma, and Verastem outside the submitted work; grants from Janssen and Abbvie outside the submitted work; and grants and personal fees from Eisai, Takeda, Mundipharma, Kyowa Hakko Kirin, Chugai Pharma, and Ono Pharmaceutical outside the submitted work. YT, TJ, TI, TKo, and TKi report no conflict of interest.